Abbott 3Q profit falls on Solvay, Meridia costs
Wednesday, October 20, 2010 - 12:01
in Mathematics & Economics
(AP) -- Drug and medical device maker Abbott Laboratories said Wednesday its third-quarter net income dropped 40 percent on costs connected with its purchase of Solvay Pharmaceuticals and its decision to withdraw the diet drug Meridia from the U.S. and Canadian markets.